Profile
Breakout Ventures is a venture capital firm based in San Francisco, California, founded in 2016. The firm is led by a team of scientists and operators with deep technical expertise and commercial fluency, focusing on scaling scientific innovation. They are known for their rigorous partnership approach and their ability to recognize market inflection points early.
The firm invests in early-stage companies operating in sectors such as biotechnology, healthcare, sustainability, and materials. They typically invest in Seed and Series A rounds, with check sizes ranging from $500K to $6M. Breakout Ventures manages several funds, including Breakout Ventures Fund II with $113M AUM launched in 2021, and Fund III with $114M AUM launched recently.
Notable investments by Breakout Ventures include CytoVale - diagnosing immune-mediated diseases, Modern Meadow - sustainable biofabrication, STRM.BIO - in vivo gene therapy, Ecovative Design - mycelium-grown materials, and Twelve - transforming carbon dioxide emissions into useful chemicals.
Industry
Breakout Ventures Funds
| Name | Type |
|
|
|
Size | AUM | Launch date |
|---|---|---|---|---|---|---|---|
|
Breakout Ventures Fund II
|
Venture Capital (VC)
|
Food and Beverage
Foodtech
Healthcare Services
Energy
HealthTech
|
Pre-seed
Seed
|
North America
|
$5-10 m
|
$113 M
|
December 2021
|
|
Fund III
|
Biotechnology
Chemicals
Medical Devices
Pharmaceuticals
Software
AI
Energy
CleanTech
Cybersecurity
Internet of Things (IoT)
HealthTech
Machine Learning (ML)
|
Pre-seed
Seed
Series A
|
North America
Europe
Asia
|
$1-5 m
|
—
|
September 2026
|
Contacts
Instant access on the web. Plans from $129/month — see pricing.